SYNLOGIC, INC.
SYBX · OTCMCIK 1527599fmd_039EYRZHDFRAT4FM7V9860Y8MCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 3 | 2 | 1 | 2 | 1 | 3 | 0 | 0 |
| Research and development | 15 | 30 | 38 | 42 | 47 | 47 | 52 | 44 | 9 | 0 |
| Total operating expenses | 21 | 43 | 54 | 57 | 61 | 63 | 69 | 59 | 41 | 4 |
| Operating income | (21) | (41) | (51) | (54) | (60) | (61) | (67) | (55) | (41) | (4) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 3 | 3 | 1 | 0 | 1 | (6) | 18 | 3 |
| Income before taxes | – | – | – | – | – | – | (66) | (61) | (23) | (1) |
| Income tax expense | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | (66) | (61) | (23) | (1) |
| Net income | (21) | (40) | (48) | (51) | (59) | (61) | (66) | (61) | (23) | (1) |
| Net income to common shareholders | (26) | – | – | – | – | – | – | – | – | – |